Welcome to our dedicated page for Bio Essence news (Ticker: BIOE), a resource for investors and traders seeking the latest updates and insights on Bio Essence stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio Essence's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio Essence's position in the market.
Bio Essence (OTCQB: BIOE) will acquire the MediFlow AI platform from Zhituo Software for USD $3,500,000, payable in restricted common stock. The Purchased Assets include software source and object code, system architecture, databases, proprietary algorithms, and technical frameworks.
The transaction is expected to close within 45 days, subject to customary conditions and board approval, and aims to expand Bio Essence's personalized digital wellness offerings.
Bio Essence Corp (OTCQB:BIOE) announced approval to upgrade to the OTCQB Venture Market, effective February 26, 2026. The company said the move reflects its commitment to enhanced transparency, regulatory compliance, and widened investor access.
The upgrade is expected to provide increased market visibility, access to real-time Level 2 quotations, and broader exposure while BIOE maintains ongoing OTCQB reporting and verification requirements.
Bio Essence Corp (OTC Pink: BIOE) announced a Regulation A, Tier 2 offering to raise up to $5.0 million by selling up to 100,000,000 shares at $0.05 per share, dated February 3, 2026. The company plans to use net proceeds to expand core operations and accelerate its AI-enabled health platform initiatives.
Planned uses include product R&D, branding, an AI-enabled digital health platform (telemedicine, diagnostics, holistic medicine, online classes, personalized nutrition), operations and compliance, and general working capital. Offering documents are available via the company.